- Exagen Inc XGN shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the consensus of $11.48 million.
- Its flagship AVISE CTD test, including AVISE Lupus, raked in $10.4 million in sales with the 94% Y/Y growth, indicating an acceleration from ~22% YoY recorded in Q1 2021. Exagen delivered 33,328 AVISE CTD tests, an 80% Y/Y increase.
- Exagen CEO Ron Rocca attributed the outperformance to the higher retention rate. "The foundation for these records was driven by our 99% retention rate, which we believe attests to the value Exagen's unique tests provide to rheumatologists and their patients," he said.
- However, operating expenses surged 49% Y/Y to $18.5 million, expanding net loss by 88% Y/Y to $6.4 million.
- But EPS loss swelled from $(0.38) from $(0.27) a year ago, beating the consensus of $(0.44).
- The cash and cash equivalents stood at $112.6 million.
- Outlook: For FY21, Exagen reaffirms its prior guidance and expects revenue of $47 million - $49 million.
- Price Action: XGN shares are up 25.7% at $12.88 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in